Swedish researchers report in the British Journal of Cancer on their examination of the tissue proteome of endometrioid endometrial cancer, or EEC, and how genomic stability affects that proteome. Using 2D gel electrophoresis and MALDI-TOF MS, the researchers identified proteins that were differentially expressed in EEC, and further examined some of those proteins in a precursor lesion to EEC. "We showed that changes in expression of proteins typical for EEC could already be detected in precursor lesions, that is, atypical hyperplasia of endometrium, highlighting their clinical potential for improving early diagnostics of EEC," they researchers say.
CXCL12, a chemokine, predicts survival in ovarian cancer, Nottingham researchers report in the British Journal of Cancer. The researchers examined CXCL12 and CXCR4 expression in 289 primary ovarian cancers, and correlated that expression to clinicopathological variables. "High expression of CXCL12 was seen in only 20 [percent] of the tumors, suggesting a role for anti-CXCL12/CXCR4 therapy in the management of these patients," the Nottingham group writes.
Finally, University of Edinburgh's David Weller and his colleagues present the Aarhus statement in the British Journal of Cancer. The group developed a consensus statement and checklist concerning early cancer diagnosis research. The checklist includes points on the study having clear time points and intervals, as well as on referring to the theoretical validation and framework of the study, among others. "The Aarhus checklist is a resource for early cancer-diagnosis research that should promote greater precision and transparency in both definitions and methods. Further work will examine whether the checklist can be readily adopted by researchers, and feedback on the guidance will be used in future updates," Weller and his colleagues say.